NEW YORK, June 30, 2011 /PRNewswire/ —
- Company remains committed to speeding innovation to patients
and delivering value to customers.
- R&D pipeline boasts 70 potential medicines in clinical
development, including 33 in Phases II and III.
- Company expects at least ten potential new medicines in
Phase III by the end of 2011, representing opportunities to improve
patient outcomes in core therapeutic areas such as neuroscience,
diabetes and oncology, as well as new areas such as
- Performance of currently marketed brands and three
counter-cyclical growth engines of Japan, emerging markets and
Elanco animal health expected to significantly counteract patent
- Productivity gains continue to reduce the company’s cost
structure and create the capacity to fund R&D and business
development, as well as to maintain the dividend.
- Consistent with previous guidance, financial outlook for
2011-2014 predicts at least $20 billion of revenue, $3 billion of
net income and $4 billion of operating cash flow annually, with a
return to growth after 2014 fueled by new product
At its meeting today with the investment community aptly
entitled “Bridging to the Future,” Eli Lilly and Company
LLY) highlighted how its transformation efforts and
innovation-based strategy will enable it to overcome upcoming
patent expirations and deliver the next generation of promising
medicines to patients. The company’s senior management detailed the
progress being made in its scientific labs and across Lilly’s five
business areas to increase productivity and accelerate the flow of
potential new medicines from its robust development pipeline. The
company also reaffirmed its mid-term financial outlook.
“At Lilly, our future relies upon